Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEHRICCA perioperative cisplatin + gemcitabine + rilvegostomig for high-risk resectable intrahepatic cholangiocarcinoma
2025-521302-17-00Phase 3Authorised
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Oct 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rilvegostomig, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 12 months. Planned start Oct 2025; status: authorised.
02
Drugs
rilvegostomiggemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2025-521302-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521302-17-00.